Kreb.Ns
KREB.NS operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products and medical research solutions.
Business. KREB.NS operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products and medical research solutions.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
KREB.NS operates in the pharmaceuticals industry, focusing on the development, manufacturing, and distribution of pharmaceutical products and medical research solutions.
KREB.NS exhibits a highly leveraged capital structure, with total liabilities of INR 31.53 billion and total equity of INR -1.46 billion, resulting in a debt-to-equity ratio of -1.45. The company's liquidity position is weak, as indicated by a current ratio of 0.1, suggesting significant short-term liquidity constraints. The negative free cash flow of INR -238.13 million and operating cash flow of INR -78.91 million further highlight the company's inability to generate positive cash from operations.
Profitability metrics are concerning, with a net loss of INR -269.39 million and an operating loss of INR -217.19 million. The return on equity of 18.42% is misleading due to the negative equity base, while the return on assets of -15.94% indicates poor asset utilization. These figures fall significantly below the industry median for profitability and asset efficiency, suggesting underperformance relative to peers.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits growth potential. The absence of segment or geographic breakdown in the financial data further obscures the company's risk profile.
Growth prospects are limited, with no disclosed revenue growth in the current fiscal year and no forward-looking guidance provided. The company's operating losses and negative cash flows suggest a lack of momentum or strategic investment in growth initiatives. The absence of capital expenditure data beyond INR -35.63 million also indicates minimal reinvestment in long-term capabilities.
The risk assessment highlights significant liquidity and solvency concerns, with a composite risk score indicating medium liquidity risk and low dilution risk. The company's negative net cash position after subtracting total debt is a red flag for creditors and investors. No dilution sources are identified in the risk assessment, but the company's negative equity position could necessitate future equity issuance to fund operations.
Recent filings and transcripts are not available in the provided data, limiting insight into management's strategic direction or operational updates. The absence of recent disclosures may indicate a lack of transparency or a focus on internal restructuring.
- KREB.NS is highly leveraged with a negative equity position and weak liquidity.
- The company is unprofitable, with significant operating and net losses.
- Revenue and geographic diversification are not disclosed, increasing concentration risk.
- Growth prospects are limited, with no forward-looking guidance or capital reinvestment.
- Liquidity and solvency risks are elevated, with no immediate dilution pressure identified.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- KREB.NS Market data — financials · 2026-05-28